scholarly journals The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients

2019 ◽  
Vol 11 (6) ◽  
pp. 407-414 ◽  
Author(s):  
Ashley Biswal ◽  
Jacqueline Erler ◽  
Omar Qari ◽  
Arthur A. Topilow ◽  
Varsha Gupta ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Breast Cancer Staging ◽  
Eighth Edition

Incorporating Biology Into Breast Cancer Staging: American Joint Committee on Cancer, Eighth Edition, Revisions and Beyond

2018 ◽  
pp. 38-46 ◽  
Author(s):  
Elizabeth A. Mittendorf ◽  
John M. S. Bartlett ◽  
Daphne L. Lichtensztajn ◽  
Sarat Chandarlapaty
Keyword(s):  
Breast Cancer ◽  
Tumor Biology ◽  
Staging System ◽  
Cancer Staging ◽  
Her2 Status ◽  
Breast Cancer Staging ◽  
Pathologic Evaluation ◽  
Staging Systems ◽  
Eighth Edition ◽  
The Impact

Higher-quality imaging, refined surgical procedures, enhanced pathologic evaluation, and improved understanding of the impact of tumor biology on treatment and prognosis have necessitated revisions of the AJCC breast cancer staging system. The eighth edition includes clinical and pathologic prognostic stages that incorporate biologic variables—grade, estrogen and progesterone receptor status, HER2 status, and multigene panels—with the anatomic extent of disease defined by tumor, node, and metastasis categories. The prognostic staging systems facilitate more refined stratification with respect to survival than anatomic stage alone. Because the prognostic staging systems are dependent on biologic factors, accuracy is dependent on rigorous pathologic evaluation of tumors and on administration of treatment dictated by tumor biology. It is anticipated that technological advances will facilitate even more refined determination of underlying biology within tumors and in the peripheral blood, which increasingly is being evaluated as a compartment that reflects the primary tumor and sites of distant metastases. Diseases should be staged according to the eighth edition staging system to accurately reflect prognosis and to allow standardized data collection. Such standardization will facilitate assessment of the impact of advances in diagnosis and treatment of patients with breast cancer.

scholarly journals Impact of biomarkers and genetic profiling on breast cancer prognostication: A comparative analysis of the 8th edition of breast cancer staging system

2019 ◽  
Vol 25 (5) ◽  
pp. 829-837 ◽  
Author(s):  
Esther C. Yoon ◽  
Christopher Schwartz ◽  
Edi Brogi ◽  
Katia Ventura ◽  
Hannah Wen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Comparative Analysis ◽  
Staging System ◽  
Cancer Staging ◽  
Genetic Profiling ◽  
Breast Cancer Staging ◽  
8Th Edition

Should log odds of positive lymph node be incorporated into AJCC TNM breast cancer staging system?

2008 ◽  
Vol 26 (15_suppl) ◽  
pp. 11037-11037
Author(s):  
J. Wang ◽  
S. J. Anderson ◽  
J. P. Costantino ◽  
E. P. Mamounas ◽  
J. M. Hassett ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Staging System ◽  
Cancer Staging ◽  
Positive Lymph Node ◽  
Breast Cancer Staging ◽  
Log Odds

scholarly journals Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System

2017 ◽  
Vol 22 (11) ◽  
pp. 1292-1300 ◽  
Author(s):  
Mariana Chavez‐MacGregor ◽  
Elizabeth A. Mittendorf ◽  
Christina A. Clarke ◽  
Daphne Y. Lichtensztajn ◽  
Kelly K. Hunt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Staging System ◽  
Cancer Staging ◽  
Tumor Characteristics ◽  
Breast Cancer Staging ◽  
Cancer Breast ◽  
American Joint Committee

scholarly journals Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3105
Author(s):  
Kumiko Kida ◽  
Kenneth R. Hess ◽  
Bora Lim ◽  
Toshiaki Iwase ◽  
Sudpreeda Chainitikun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Inflammatory Breast Cancer ◽  
Growth Factor Receptor ◽  
Disease Free Survival ◽  
Staging System ◽  
Cancer Staging ◽  
Cancer Center ◽  
Cancer Specific Survival ◽  
Breast Cancer Staging ◽  
Grade 3

The AJCC updated its breast cancer staging system to incorporate biological factors in the “prognostic stage”. We undertook this study to validate the prognostic and anatomic stages for inflammatory breast cancer (IBC). We established two cohorts of IBC diagnosed without distant metastasis: (1) patients treated at The University of Texas MD Anderson Cancer Center between 1991 and 2017 (MDA cohort) and (2) patients registered in the national Surveillance, Epidemiology, and End Results (SEER) database between 2010 and 2015 (SEER cohort). For prognostic staging, estrogen receptor (ER)+/progesterone receptor (PR)+/ human epidermal growth factor receptor-2 (HER2)+/grade 1–2 was staged as IIIA; ER+/PR−/HER2−/grade 3, ER−/PR+/HER2−/grade 3, and triple-negative cancers as IIIC; and all others as IIIB. Endpoints were breast cancer-specific survival (BCSS), overall survival (OS), and disease-free survival (DFS). We studied 885 patients in the MDA cohort and 338 in the SEER cohort. In the MDA cohort, the prognostic stage showed significant predictive power for BCSS, OS, and DFS (all p < 0.0001), although the anatomic stage did not. In both cohorts, the Harrell concordance index (C index) was significantly higher in the prognostic stage than the anatomic stage for all endpoints. In conclusion, the prognostic stage provided more accurate prognostication for IBC than the anatomic stage. Our results show that the prognostic staging is applicable in IBC.

Sign in / Sign up

Export Citation Format

Share Document